Converted to an active metabolite. Inhibits DNA synthesis as also that of RNA and protein. May be selectively toxic to hypoxic cells because it may generate superoxide and hydroxylradicals. Effects are most marked in the late G1 and early S phases of cell cycle.
Ademocarcinoma, lymphosarcoma and seminoma. Superficial bladder cancer as a adjuvant in primary or recurrent pterygia.
After oral administration it exhibits inconsistent absorption. Hence it is administered by intravenous route. It is metabolised in liver.
Haemorrhagic tendencies, bone marrow depression, not to be given I.M. or S.C., thrombocytopenia.
Nausea, vomiting, allergic reactions, fever, alopecia, pulmonary fibrosis, bone marrow depression, renal toxicity, sterility, stomatitis, amenorrhoea.
Leucopenia, mouth ulcers. Monitor renal function and haematological status.
Terminal elimination half-life 50 mins.
2mg Injection,
|
|||||||||||||||||||
|
Disclaimer
:
This guide is provided for information purposes only, and for use
of a registered medical practitioner or a hospital or a laboratory only.
The authors, webmaster, or respective references / links are no way
responsible for the content of the information. Although a concerted
effort has been made to ensure the validity of the information contained
in this document, we give no
assurance for the accuracy of the information in this documents. |